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BSTRACT
 
Background
 
Although smoking cessation is de-
sirable from a public health perspective, its conse-
quences with respect to health care costs are still
debated. Smokers have more disease than nonsmok-
ers, but nonsmokers live longer and can incur more
health costs at advanced ages. We analyzed health
care costs for smokers and nonsmokers and esti-
mated the economic consequences of smoking ces-
sation.
 
Methods
 
We used three life tables to examine the
effect of smoking on health care costs — one for a
mixed population of smokers and nonsmokers, one
for a population of smokers, and one for a popula-
tion of nonsmokers. We also used a dynamic meth-
od to estimate the effects of smoking cessation on
health care costs over time.
 
Results
 
Health care costs for smokers at a given
age are as much as 40 percent higher than those for
nonsmokers, but in a population in which no one
smoked the costs would be 7 percent higher among
men and 4 percent higher among women than the
costs in the current mixed population of smokers
and nonsmokers. If all smokers quit, health care
costs would be lower at first, but after 15 years they
would become higher than at present. In the long
term, complete smoking cessation would produce a
net increase in health care costs, but it could still be
seen as economically favorable under reasonable
assumptions of discount rate and evaluation period.
 
Conclusions
 
If people stopped smoking, there
would be a savings in health care costs, but only in
the short term. Eventually, smoking cessation would
lead to increased health care costs. (N Engl J Med
1997;337:1052-7.)
 
©1997, Massachusetts Medical Society.
 
From the Department of Public Health, Erasmus University, P.O. Box
1738, 3000 DR Rotterdam, the Netherlands, where reprint requests
should be addressed to Mr. Barendregt.
 
MOKING is a major health hazard, and since
nonsmokers are healthier than smokers, it
seems only natural that not smoking would
save money spent on health care. Yet in eco-
nomic studies of health care it has been difficult to
determine who uses more dollars — smokers, who
tend to suffer more from a large variety of diseases,
or nonsmokers, who can accumulate more health
care costs because they live longer. The Surgeon
General reported in 1992 that “the estimated aver-
age lifetime medical costs for a smoker exceed those
for a nonsmoker by more than $6,000.”
 
1
 
 On the
other hand, Lippiatt estimated that a 1 percent de-
cline in cigarette sales increases costs for medical
care by $405 million among persons 25 to 79 years
S
 
old.
 
2
 
 Manning et al. argued that although smokers
incur higher medical costs, these are balanced by to-
bacco taxes and by smokers’ shorter life spans (and
hence their lower use of pensions and nursing
homes).
 
3
 
 Leu and Schaub showed that even when
only health care expenditures are considered, the
longer life expectancy of nonsmokers more than off-
sets their lower annual expenditures.
 
4
 
 
We have analyzed comprehensively the health care
costs of smoking. In doing so we have distinguished
between the assessment of differences between smok-
ers and nonsmokers and the assessment of what
would happen after interventions that changed smok-
ing behavior. Would a nonsmoking population have
lower health care costs than one in which some peo-
ple smoke? Are antismoking interventions economi-
cally attractive? We sought to answer these questions
and to determine the consequences for health policy.
 
METHODS
 
Analysis of Smokers and Nonsmokers
 
We examined the effect of smoking in the general population
(a mixture of smokers and nonsmokers). We studied the inci-
dence, prevalence, and mortality associated with five major cate-
gories of disease — heart disease, stroke, lung cancer, a heteroge-
neous group of other cancers, and chronic obstructive pulmonary
disease (COPD). We used data on these diseases, in addition to
mortality from all other causes, in an extension of the standard
life table, the multistate life table, that includes multiple health
states, such as “alive, healthy” and “alive, with heart disease.”
 
5,6
 
 
Differences in the frequency of the smoking-related diseases
between smokers and nonsmokers are commonly expressed as
rate ratios. Using these rate ratios, the prevalence of smoking in
the population, and the age- and sex-specific incidence of the
smoking-related diseases in the mixed population of smokers and
nonsmokers, we can estimate the incidence of the diseases sepa-
rately among smokers and nonsmokers.
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Assuming that the relative survival of persons with these diseas-
es is the same among both smokers and nonsmokers, two addi-
tional life tables can be calculated — one for smokers and one for
nonsmokers. The three life tables differ with regard to the inci-
dence of the smoking-related diseases and therefore in their asso-
ciated prevalence, disease-specific mortality, and overall mortality.
Because of the difference in mortality, more people remain alive
in the life table for nonsmokers than in the table for smokers, par-
ticularly in the older age groups, and there are corresponding dif-
ferences in life expectancies.
In constructing the life tables, we used epidemiologic data on
the incidence and prevalence of the diseases,
 
7-10
 
 data on mortality
from Statistics Netherlands,
 
11
 
 data on smoking (Table 1),
 
12
 
 and
rate ratios from an overview of the literature.
 
13
 
 We tested the sen-
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sitivity of the analysis by recalculating the life tables with excess
risks (the rate ratio
 

 
1) that were 50 percent higher and 50 per-
cent lower (Table 2).
The medical costs we used were based on a study that allocated
the total costs for health care in the Netherlands in 1988 (39.8
billion guilders, or $19.9 billion, at the present exchange rate) to
categories of age, sex, and disease.
 
14
 
 We used the Dutch popula-
tion in 1988 and the prevalence rates of the smoking-related dis-
eases from the life table for mixed smokers and nonsmokers to
estimate the costs per case of disease according to age and sex.
The remaining costs were assigned to “per capita costs for all oth-
er diseases” (in categories according to age and sex) by dividing
the costs by the number of people in the category in question.
Using the per capita costs for each disease and the “all other dis-
ease” costs, we calculated the health care costs for the populations
included in the three life tables.
 
Assessment of the Effect of Complete Smoking Cessation
 
The estimated health care cost derived from the life table of
nonsmokers can be seen as an estimate of the cost of health care
if no one ever smoked. It does not provide an estimate of the
health care cost if all smokers stopped smoking. In the latter case,
the size of the elderly population would initially be the same as
in the mixed population of smokers and nonsmokers. For it to be-
come similar in size to the elderly population among nonsmokers,
in which more elderly people are alive, would take several years,
even if mortality declined rapidly.
To describe the epidemiologic changes and the changes in the
population over time, a dynamic model is needed. For this purpose,
we needed a series of linked life tables, one for each point in time,
with the population at a given age (
 
a
 
) and time (
 
t
 
) depending on
the population at age 
 
a
 

 
1
 
 and time 
 
t
 

 
1,
 
 and on the incidence of
disease and the associated mortality between 
 
t
 

 
1
 
 and 
 
t.
 
 We used
the Prevent Plus computer program, which is designed to evaluate
interventions concerning risk factors dynamically.
 
6,15
 
 
This dynamic analysis produces a projection of future health
care costs. To assess the economic attractiveness of an interven-
tion that would make smokers quit, these costs are compared
with those expected when no intervention is made. One difficulty
in such an evaluation is the fact that most people prefer to receive
benefits as soon as possible and to postpone payments. Econo-
mists call this phenomenon “time preference,”
 
16,17
 
 and it is taken
into account by discounting the future benefits and costs — that
is, those further away in time are given lower weights in the over-
all evaluation.
The degree of time preference is expressed in the discount rate.
Typical values range from 0 to 10 percent, with 0 percent mean-
ing that there is no discounting and no time preference and 10
percent meaning that there is a strong time preference. Since
there is no generally agreed-upon discount rate, we used various
rates (0, 3, 5 and 10 percent) in evaluating the intervention.
A second difficulty in evaluating future costs and benefits is de-
ciding how far into the future the analysis should go. There is no
generally agreed-upon duration of follow-up in this type of analysis.
For each projection of discounted costs and benefits, we therefore
report the duration of follow-up at which the benefits and costs ex-
pected in the future exactly balance each other (the break-even
year) — the point at which carrying out the intervention is neither
more nor less economically attractive than not doing so.
 
RESULTS
 
Figure 1 shows the annual per capita health care
costs for male smokers and nonsmokers 40 to 89
years old, in 5-year age groups (the costs for women
in the same age groups are very similar). Per capita
costs rise sharply with age, increasing almost 10
times from persons 40 to 44 years of age to those
85 to 89 years of age. In each age group, smokers
incur higher costs than nonsmokers. The difference
varies with the age group, but among 65-to-74-year-
olds the costs for smokers are as much as 40 percent
higher among men and as much as 25 percent high-
er among women.
However, the annual cost per capita ignores the dif-
ferences in longevity between smokers and nonsmok-
ers. These differences are substantial: for smokers, the
life expectancies at birth are 69.7 years in men and
75.6 years in women; for nonsmokers, the life expect-
ancies are 77.0 and 81.6 years (these life-table esti-
mates agree very well with the empirical findings of
Doll et al.
 
18
 
). This means that many more nonsmok-
ers than smokers live to old age. At age 70, 78 percent
of male nonsmokers are still alive, as compared with
only 57 percent of smokers (among women, the fig-
ures are 86 percent and 75 percent); at age 80, men’s
 
*Data are averages for 1988–1992 in the Nether-
lands.
 
12
 
T
 
ABLE
 
 1.
 
 P
 
REVALENCE
 
 
 
OF
 
 S
 
MOKING
 
.*
 
A
 
GE
 
 (
 
YR
 
) S
 
MOKERS
 
MALE FEMALE
 
percent
 
0–14 0 0
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20–34 39 37
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*Rate ratios refer to the rate of the disease in
smokers as compared with nonsmokers. The lower
and upper bounds of the sensitivity range were cal-
culated as 1
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1), re-
spectively, where RR denotes the rate ratio.
†This category includes neoplasms except for
stomach, colorectal, lung, breast, prostate, and skin
cancers, and benign tumors.
‡COPD denotes chronic obstructive pulmonary
disease.
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COPD‡ 25 (13–37)
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survival is 50 percent and 21 percent, respectively
(among women, 67 percent and 43 percent).
These differences in the numbers of elderly people
have a profound effect on the health care costs for
the population, as Figure 1 shows. In the younger
age groups, in which mortality even among smokers
is quite low, a population of smokers has higher
health care costs than a population of nonsmokers,
but in the groups of men 70 to 74 and over (and
those of women 75 to 79 and over), the lower per
capita cost of the nonsmokers is outweighed by the
greater number of people remaining alive.
As Figure 1 shows, the nonsmoking population as
a whole is more expensive than the smoking popu-
lation. The area between the curves in which the
smokers have higher health care costs than the non-
smokers is smaller than the area between the curves
in which the nonsmokers have higher health care
costs than the smokers. This is shown in greater de-
tail in Table 3, where the total health care costs for
the mixed, the smoking, and the nonsmoking pop-
ulations are presented according to disease category.
All the smoking-related diseases (with the nota-
ble exception of stroke among men) are associated
with higher costs in a population of smokers and
lower costs in a population of nonsmokers. This re-
lation is particularly strong for the diseases with the
highest excess risk: lung cancer and COPD. Howev-
er, in the mixed population of smokers and non-
smokers, smoking-related diseases account for only
19 percent of total costs among men and 12 percent
of total costs among women, and the costs of all the
other diseases have precisely the opposite relation.
In a population of smokers, the costs associated with
all the other diseases are less than those in the mixed
population: 14 percent less for men and 18 percent
less for women. Among nonsmokers, the costs of all
the other diseases are 15 percent higher for men and
7 percent higher for women.
The risk of the diseases not related to smoking is
 
Figure 1.
 
 Estimated Annual per Capita Health Care Costs for Dutch Men in 1988 and
for the Male Population in a Life Table, According to Age and Smoking Status.
Per capita health care costs for women in the same age groups are very similar to
those for men.
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considered equal for smokers and nonsmokers, but
the nonsmoking population lives longer and there-
fore incurs more costs due to those diseases, partic-
ularly in old age, when the costs are highest. On bal-
ance, the total costs for male and female nonsmokers
are 7 percent and 4 percent higher, respectively, than
for a mixed population, whereas for smokers the to-
tal costs are 7 percent and 11 percent lower.
Table 3 also shows that changing the assumptions
about the excess risk associated with smoking-relat-
ed diseases by as much as 50 percent in either direc-
tion does not change the conclusion, except in the
case of stroke. The age-related increase in incidence
is steepest for stroke, and there is also an age-related
increase for stroke in the cost per case; therefore the
health care costs associated with stroke are the most
sensitive to changes in life expectancy.
Because of the costs of other diseases, the popu-
lation of nonsmokers has higher health care costs,
partly because these costs increase with age. To test
the sensitivity of the analysis to this age-related in-
crease, we recalculated the three life tables, keeping
 
Figure 2.
 
 Percent Changes in Total Health Care Costs for the
Male Population after Smoking Cessation, as Determined in a
Dynamic Analysis, According to the Number of Years since
Cessation, with No Discounting and with Three Discount Rates.
The labels show the “break-even” years, when the cost and
benefit of the intervention balance each other. Shorter follow-
up times make smoking cessation attractive economically, and
longer follow-up makes it unattractive. With 10 percent dis-
counting, the break-even year is later than 50 years.
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2. A lower rate ratio reduces the difference between smokers and nonsmokers in the incidence, prev-
alence, and mortality from smoking-related disease. Therefore, nonsmokers avert fewer cases of smok-
ing-related disease (leading to lower savings) but simultaneously gain less in life expectancy (leading
to lower added costs from “other” diseases). For most smoking-related diseases and “other” diseases,
lower rate ratios make the difference in costs smaller.
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millions of $ cost ratio (sensitivity range)†
Men
Heart 525 676 371 1.29 (1.18–1.35) 0.71 (0.84–0.61)
Stroke 416 390 428 0.94 (0.91–0.97) 1.03 (1.06–0.98)
Lung cancer 114 211 33 1.85 (1.76–1.87) 0.29 (0.44–0.22)
Other cancers 226 254 203 1.12 (1.05–1.18) 0.90 (0.97–0.83)
COPD 165 275 23 1.67 (1.72–1.63) 0.14 (0.23–0.11)
All other 6,360 5,463 7,284 0.86 (0.89–0.84) 1.15 (1.09–1.18)
Total 7,806 7,270 8,342 0.93 (0.95–0.92) 1.07 (1.04–1.09)
Women
Heart 386 538 330 1.39 (1.24–1.48) 0.86 (0.93–0.79)
Stroke 510 571 502 1.12 (1.04–1.19) 0.98 (1.01–0.96)
Lung cancer 23 70 9 3.10 (2.61–3.32) 0.39 (0.55–0.31)
Other cancers 297 387 264 1.30 (1.16–1.42) 0.89 (0.95–0.84)
COPD 102 254 20 2.48 (2.45–2.45) 0.20 (0.31–0.15)
All other 9,358 7,653 10,013 0.82 (0.87–0.79) 1.07 (1.04–1.09)
Total 10,676 9,473 11,138 0.89 (0.92–0.87) 1.04 (1.03–1.05)
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the health care costs associated with “all other dis-
ease” at the 65-to-69-year-old level for people over
the age of 65. The costs for the mixed population
and for the nonsmoking population became virtual-
ly the same, and those for the smoking population
were still the smallest, albeit by a small margin. 
Figure 2 shows what the economic consequences
would be if all smokers stopped smoking. After this
abrupt change, the total health care costs for men
(the “no discounting” curve) would initially be low-
er than they would have been (by up to 2.5 percent),
because the incidence of smoking-related diseases
among the former smokers would decline to the lev-
el among nonsmokers. Prevalence rates start to de-
cline, costs decline, and the intervention shows a
benefit. With time, however, the benefit reverses it-
self to become a cost. The reason is that along with
incidence and prevalence, smoking-related mortality
declines and the population starts to age. Growing
numbers of people in the older age groups mean
higher costs for health care. By year 5, the benefit de-
rived from the presence of the new nonsmokers
starts to shrink, and by year 15 these former smokers
are producing excess costs. Eventually a new steady
state is reached in which costs are about 7 percent
higher — the difference between the mixed and the
nonsmoking populations.
Figure 2 shows the consequences of discounting
the projected costs and benefits by various percent-
ages. It is apparent that discounting, even at a rate as
low as 3 percent, has a huge impact, and this impact
becomes greater as the costs become more distant
in time.
Having all smokers quit becomes economically at-
tractive when the future benefits are larger than the
future costs or, in terms of Figure 2, when the area
below the x axis is bigger than the area above it.
From the figure it is clear that this depends heavily
on the duration of follow-up considered and on the
discount rate. With a shorter evaluation period and
higher discount rates, stopping smoking looks eco-
nomically more attractive. With a longer evaluation
period and lower discount rates, quitting smoking
loses its economic advantages. The break-even year,
when the initial benefit is exactly balanced by the
eventual cost, occurs after 26 years of follow-up when
there is no discounting, after 31 years with 3 percent
discounting, and after 37 years with 5 percent dis-
counting. At 10 percent discounting, the break-even
year occurs after more than 50 years and may not oc-
cur at all.
DISCUSSION
This study shows that although per capita health
care costs for smokers are higher than those of non-
smokers, a nonsmoking population would have high-
er health care costs than the current mixed popula-
tion of smokers and nonsmokers. Yet given a short
enough period of follow-up and a high enough dis-
count rate, it would be economically attractive to
eliminate smoking.
Some earlier studies have had differing results,
partly because many have focused on costs attribut-
able to smoking. From rate ratios and the prevalence
of smoking in a population, the proportion of the
total number of cases of a disease that can be attrib-
uted to smoking — the population attributable risk
— can be calculated.19 Given the costs according to
disease, one can calculate the costs attributable to
smoking.20 For instance, in the life-table population
of mixed smokers and nonsmokers about 8 percent
of total health care costs among men and almost
3 percent of total costs among women can be attrib-
uted to smoking. Attributable costs, however, can be
interpreted as potential savings only when the dis-
eases do not affect mortality. In the case of most
smoking-related diseases, reductions in smoking re-
duce mortality, creating new possibilities for mor-
bidity from other diseases in the years of life gained.
Other studies of this subject estimate lifetime
health care costs, taking the differences in life expect-
ancy into account, and find that smokers have high-
er medical costs.3,21,22 In our study, lifetime costs
for smokers can be calculated as $72,700 among
men and $94,700 among women, and lifetime costs
among nonsmokers can be calculated as $83,400
and $111,000, respectively. This amounts to lifetime
costs for nonsmokers that are higher by 15 percent
among men and 18 percent among women.
The studies cited above apply discounting to the
lifetime cost estimate. Because costs incurred at old-
er ages are discounted more, this approach reduces
lifetime costs for nonsmokers more than those for
smokers. For example, when one applies discount-
ing to our life tables for smokers and nonsmokers,
smokers have higher health care costs when the dis-
count rate is at least 4.5 percent in men or at least
5.5 percent in women. We disagree with this ap-
proach, however. Discounting should be used for
purposes of evaluation and should not be applied in
a descriptive context, such as the estimation of life-
time costs.
Our analysis is not very sensitive to substantially
different values in the rate ratio. Neither is it very
sensitive to the age-related increase in the cost of “all
other diseases”; that is, an increase that is less steep
in the United States than in the Netherlands will not
lead to different conclusions. Including additional
smoking-related diseases could change the results
only if those diseases generate morbidity and costs
without raising the excess risk of mortality. There
may be some of these conditions, such as cataracts,
but they are unlikely to change outcome. For exam-
ple, in our data all eye diseases, most of which are
not related to smoking, account for about 1 percent
of total health care costs.
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This study relied on rate ratios from epidemiologic
studies to express the differences between smokers
and nonsmokers. To the extent that the rate ratios do
not describe these differences sufficiently, the results
will be affected. For example, the much lower cost
for lung cancer among female smokers than among
male smokers (Table 3) is hard to explain physiolog-
ically. But as long as the smokers have higher rates
of lung cancer than the nonsmokers, such shortcom-
ings of the data will not affect the overall conclu-
sions.
The results of this study illustrate the ambiguities
in any economic method of evaluation. Even a well-
designed study of this type is marred by inevitable
arbitrariness concerning what costs to include, which
discount rate to apply, and what duration of follow-
up to use. There are differences of opinion — on the
discounting of lifetime costs, for example, and the
evaluation of long-term effects.23,24 Recent efforts at
standardization will remedy some of the arbitrari-
ness,25-27 but fundamental problems with the meth-
od still remain.
Finally, with respect to public health policy, how
important are the costs of smoking? Society clearly
has an interest in this matter, now that several states
are trying to recoup Medicaid expenditures from to-
bacco firms and the tobacco companies have agreed
to a settlement. Yet we believe that in formulating
public health policy, whether or not smokers impose
a net financial burden ought to be of very limited
importance. Public health policy is concerned with
health. Smoking is a major health hazard, so the ob-
jective of a policy on smoking should be simple and
clear: smoking should be discouraged.
Since we as a society are clearly willing to spend
money on added years of life and on healthier years,
the method of choice in evaluating medical inter-
ventions is cost-effectiveness analysis, which yields
costs per year of life gained. Decision makers then
implement the interventions that yield the highest
return in health for the budget.28 We have no doubt
that an effective antismoking policy fits the bill.
Supported by the Dutch Ministry of Health.
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